antiphospholipid antibody syndrome
TRANSCRIPT
![Page 1: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/1.jpg)
ANTIPHOSPHOLIPID
ANTIBODY SYNDROME
Dr.Praveen Nagula
![Page 2: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/2.jpg)
A discovery is said to be an accident meeting a prepared mind.
A discovery is said to be an accident
meeting a prepared mind.
A discovery is said to be an accident meeting a prepared
mind
![Page 3: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/3.jpg)
Case description in brief.
A young female was admitted in casualty with swelling of rt lower limb.
On examination pulses absent. USG showed thrombus. h/o revealed –marriage life 0f 18 months---2 months later had
an ischemic stroke---after 7 months became pregnant---6 months miscarriage,severe pl. insufficiency---after 2 months she had swelling of rt lower limb—DVT---on 1st june had abd pain—hemorrhagic cyst of ovary—stopped acitrom---DVT.
INR---3.3 at discharge Diagnosis suspected of APLS APL ab positive---Ig G ACL—90GPL,IgM ,IgA were positive. Patient was kept on warfarin----to be followed up.
![Page 4: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/4.jpg)
INTRODUCTION
Also known as HUGHES SYNDROME.
LUPUS ANTI COAGULANT SYNDROME (misnomer)
Autoimmune disorder.----acquired thrombophilic disorder.
Mostly assosciated with SLE.
Responsible for frequent miscarriages in young females (15%).
CATASTROPHIC APS---Asherson’s syndrome.
MC thrombotic defect leading to fetal wastage.
![Page 5: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/5.jpg)
Graham R.V. Hughes
![Page 6: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/6.jpg)
DEFINITION
A patient with definite APS must have persistent high titer antiphospholipid antibodies(APL) assosciated with a history of arterial or venous thrombosis or both ,or recurrent pregnancy morbidity.—(clinical criteria) and laboratory criteria.
CAPS Asymptomatic antiphospholipid antibodies Probable antiphospholipid syndrome Seronegative antiphospholipid syndrome(SNAP) Microangiopathic antiphospholipid syndrome Drug induced Infection assosciated Malignancy assosciated.
![Page 7: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/7.jpg)
CLINICAL CRITERIA—( SAPPORO CRITERIA)
APS is present if at least one of the clinical criteria and one of the laboratory criteria that follow are met….
Clinical criteria---1.vascular thrombosis One or more clinical episodes of arterial,venous or small
vessel thrombosis,occuring in any tissue or organ.to be confirmed by objective validated criteria.histopathologically thrombosis should be present without significant evidence of inflammation in the vessel wall.
2.pregnancy morbidity a.one or more unexplained deaths of morphologically normal
fetuses at or after the 10 week of gestation. b.one or more premature births of morphologically normal
neonates before the 34th week of gestation—ecclampsia,sev pl insufficiency
c.three or more unexplained consequtive sp abortions before the 10th week of gestation—anatomic,hormonal abn excluded.
![Page 8: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/8.jpg)
Sapporo,JAPAN…SYDNEY
![Page 9: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/9.jpg)
Laboratory criteria 1.lupus anticoagulant present in plasma. 2.aCL of IgG and or IgM isotype in serum or
plasma,present in medium or high titer(>40GPL,40MPL,>99TH percentile)
3.anti β2GP1IgG or IgM isotype in serum or plasma
On two or more occasions at least 12 weeks apart.
Diagnostic clues for individual patients but not as classification criteria for the purpose of clinical trials
Cardiac valve disease,livedo reticularis,thrombocytopenia,renal thrombotic microangiopathy,neurological manifestations-chorea
Non criteria antibodies—IgAaCL,IgAanti Β2gp1,antiphosphatidylserine ab,antiphosphatidyl ethanolamine ab,ab against prothrombin alone,ab to Ph.serine-PT complex.
![Page 10: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/10.jpg)
criteria
![Page 11: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/11.jpg)
![Page 12: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/12.jpg)
Advances in criteria 1999---sapporo concensus conference 2004---sydney conference revised Numerous modifications were made to the initial statement.
Better defining of clinical criteria by confirmation. Stratification of patients with APS presence or absence of other
inherited or acquired contributing cause of thrombosis.
APS with or without assosciated rheumatic disease. CAPS Asymptomatic aPL Time interval increased to 12 weeks Transient positivity to be excluded Add of b2gp1 ab Diagnostic clues J thromb haemost
2006:4:295-306 Arthritis Rheum
1999;42:1309-11 JAPI,mar 2010—176-183
![Page 13: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/13.jpg)
EPIDEMIOLOGY In young,app healthy people---for LA,antiCL is 1-5% Prevalence ↑ with age ,in elderly with chronic disease. Risk of thrombosis is 0.5-30% Women :men is 5:1 Mean age of onset-31 yrs Low age 8 months Females---arthritis,livedo,migraine Males—MI,epilepsy,lower extremity arterial thrombosis ACA ass with thrombosis>LA ---5:1 Acl in elderly More common in african americans.
Without rheumatic disease at younger age and with rh –older
Apl ab—30-40% in SLE---10% have APLS Idiopathically—ACL-24%,LA-4%
![Page 14: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/14.jpg)
The clinical manifestation of thrombosis is similar whether the APL is primary or secondary.
Removed in 2006.
Common auto immune diseases ass with APL ab are 1.SLE-25-50% 2.sjogren’s –42% 3.RA-33% 4.AITP-30% 5.AIHA-unknown 6.PA-28% 7.SS-25% 8.MCD-22% 9.behcet-20% 10.PMR-20%
![Page 15: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/15.jpg)
etiology
Unknown cause Possible triggers identified and stratified accordingly. Most of the autoimmune disorders ass with APLab WHETHER IT ITSELF INVOLVED IN PATHOGENESIS OR
IS AN EPIPHENOMENON IS ? Relatives of persons with known APS—33% freq have
APLab HLA –DRW53,DR7—HISPANIC,DR4 white.
![Page 16: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/16.jpg)
PATHOGENESIS
Homeostatic regulation of blood coagulation is altered.
1.defect in cellular apoptosis---exposure of membrane phospholipids to the binding of various plasma proteins---b2gp1---complex—epitope---target for autoantibodies.
2.oxidized b2GP1---activates dendritic cells –autoantibodies are produced.
3.production of antibodies against prothrombin,proteinC,S annexins.
4.activation of platelets to enhance endothelial adherence.
5.activation of vascular endothelium—platelet and monocyte binding.
6.ab against oxidized LDL—atherosclerosis.
![Page 17: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/17.jpg)
Complement activation has been increasingly recognised as a possible significant role in the pathogenesis of APS.
Blood. Jan 15 2007;109(2):422-30.
Nat Med. Nov 2004;10(11):1222-6.
The family of APL ab are heterogenous and the targets vary.
APS can be caused by –LA,ACA,B2GP1 or other antibodies.
There are distinct clinical ,laboratory and biochemical differences between the disorders mediated by the different antibodies.
ACL---risk of stroke—arterial thrombosisLA-venousTNF alpha –pregnancy loss
![Page 18: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/18.jpg)
Mechanism of thrombosis
Precise mechanism is unclear. Heterogenous---several mechanisms are responsible.
‘phospholipids are an integral part of platelet And endothelial cell surface membranes ,it is expected that these antibodies have a effect on them.’
![Page 19: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/19.jpg)
How do they mediate????
Inhibition of endothelial cell prostacyclin production Clin Appl Thromb Hemost 1999;5;s76
Procoagulant effect on platelets Br J Haematol 2002:119;781
Impairement of fibrinolysis Interference with the thrombomodulin-proteinS-proteinC
pathway J Autoimmun 2007;28(2-3):129-33
Induction of procoagulant activity on endothelial cells and/or monocytes Clin Exp Immuno 2000;120:537
Disruption of the annexin Vcellular shield Fertil Steril 2002l;77:805
Abnormal cytotrophoblast expression of adhesion molecules in pregnancy NEJM2002;346 (10);752-63
![Page 20: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/20.jpg)
Anionic phospholipids
![Page 21: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/21.jpg)
pathology
![Page 22: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/22.jpg)
pathogenesis
![Page 23: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/23.jpg)
![Page 24: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/24.jpg)
![Page 25: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/25.jpg)
Coagulation pathway
![Page 26: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/26.jpg)
Annexin V
![Page 27: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/27.jpg)
In pregnancy
![Page 28: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/28.jpg)
ACA– are directed against cardiolipin They may be b2 gp1 dependent or independent Independent—syphilis
B2 gp1-----apolipoprotein H Bind with cardiolipin ab --thrombosis
![Page 29: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/29.jpg)
What do the animal models say???
Question the non inflammatory ,thrombotic state Evidence for complement activation is crucial for
complications in pregnancy. Inflammation mediated tissue injury in pregnancy Therapy should be against inflammation Ann N Y Acad Sci
2005 ;1051:413-20
Mouse model of APS---heparin prevents complement activation induced by APL.
Use of specific complement inhibitors in APS—future TNF alpha– as a critical effector in pregnancy loss—TNF
blockade
![Page 30: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/30.jpg)
Risk factors for thrombosis
Age >55 in men,>65 in women Risk factor for CVD* Inherited thrombophilias Oral contraceptives Nephrotic syndrome Malignancy Immobilization Surgery
*htn,DM2,LDL,↓HDL,cigarette smoking,family h/o BMI>30kg/m2,microalbuminuria,GFR<60ml/min
![Page 31: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/31.jpg)
CLINICAL FEATURES(SPECTRUM)
1.VENOUS THROMBOSIS Lower extremities 29-55% caes >50% have asymptomatic pulmonary embolism Seen at unsual sites Cerebral veins may be affected Superior sagittal sinus Semin Thromb Hemost
1999;25:333-50
![Page 32: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/32.jpg)
Superficial thrombophlebitis
![Page 33: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/33.jpg)
Retinal vein thrombosis
![Page 34: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/34.jpg)
2.ARTERIAL THROMBOSIS Less common Males Present with TIA or stroke 50%,MI(25%) Presence of anti CL ab—risk factor Involvement of large and small vessels—unique Brachial,subclavian arteries Peripheral arteries
NEJM 2002;346;752-63Dis Mon 2003;49:696-741Semin Thromb Hemost 1999:25;333-50
![Page 35: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/35.jpg)
gangrene
![Page 36: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/36.jpg)
Retinal artery thrombosis
![Page 37: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/37.jpg)
3. CARDIAC disorders Thrombotic or embolic Premature athreosclerosis—occlusion Apl inv in young age with no risk factors for CaVD Valvular thickening—M.,A Vegetations ----libmann sacks Premature coronary disease Myocardial infarction Diffuse cardiomyopathy CHF Pericardial effusion Pulmonary hypertension
In SLE---pericarditis is common,no valvular reg,with htn –HF,only epicardial ischemia.
J thromb thrombolysis 2005;20;105-12
![Page 38: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/38.jpg)
endocarditis
![Page 39: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/39.jpg)
4.NEUROLOGICAL disorders Thrombotic or embolic LA—venous,ACL—arterial---risk factor for stroke in young Recurrent strokes—multi infarct dementia No other risk factors are present “chorea is another clinical diosrder that has been strongly
linked to presence of APL” Migraine,TM,GBS,ON,ICH,psychosis Mimics multiple sclerosis—cognitive dysfunction Diff—chorea,migraine,seizure ,dysarthria mc in
apl,ON,bowel ,bladder ,gait—MS Non enhancing with gadolinium,strongly poisitive
ab---APLS
Dis Mon 2003;49(12):696-741,Thromb Res 2004;114;489-99,Ann N Y Acad Sci 2005
![Page 40: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/40.jpg)
5.obstetrical disorders Recurrent miscarriages Fetal demise Ecclampsia IUGR Oligohydramnios HELLP syndrome
May be the prsenting feature of APLS
MC thrombotic defect leading to fetal demise---15% of miscarriages
Haemtol Oncol Clin North Am 2008;22;33-52
![Page 41: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/41.jpg)
miscarriages
![Page 42: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/42.jpg)
![Page 43: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/43.jpg)
6.DERMATOLOGICAL May be the presenting feature Noninflammatory vascular thrombosis Livedo reticularis is more common Cutaneuos ulcerations Subungual splinter hemorrhages Anetoderma
Patients with livedo reticularis and APS frequently have cardiac and cerebral thrombotic events,epilepsy,migraine headaches
Cerebral---SNEDDON’S syndrome Clin Exp Rheumatol
2005;23;499-504
![Page 44: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/44.jpg)
Livedo reticularis
![Page 45: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/45.jpg)
Splinter hemorrhages
![Page 46: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/46.jpg)
anetoderma
![Page 47: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/47.jpg)
Subungual splinter hemorrhage
![Page 48: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/48.jpg)
![Page 49: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/49.jpg)
7.PULMONARY Most frequent arterial complication Thromboembolism of lung arteries ARDS Diffuse alveolar hemorrhage—non thrombotic manifestation of APS High mortality
8.ABDOMINAL Hepatic involvement is common Acalculous cholecystitis Giant gastric ulceration
9.ENDOCRINE Adrenal insufficiency Thyroid 10.RETINAL---CRAO,CRVO,ON,CiRAO 11.HEMATOLOGY-----thrombocytopenia<1,00,000. Severe—CAPS,TTP <50,000—bleeding
![Page 50: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/50.jpg)
12.RENAL APLN---renal manifestation of APLS Thrombosis at any site. Non thrombotic –glomerulonephritis 25% patients have renal ---mostly IgG ab Nil/membranous nephropathy Patient—with flank pain,RVT,proteinuria---check for APL Urine analysis---mod proteinuria,hematuria Ischemic mesangiolysis,vessel hyperplasia <10%--ARF—recurrence Warfarin,steroids,plasmapheresis Lupus
2006,15;485-9
![Page 51: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/51.jpg)
Catastrophic Antiphospholipid Syndrome(CAPS)
A syndrome of multisystem involvement . <1% of patients. Multiple small vessel occlusions---multi organ failure. Acute onset 3 different organ systems Acute microangiopathy is characteristic ARF,ARDS,CEREBRAL INJURY,MYOCARDIAL ischemia. Potentially lethal Trigger factors involved---
infections,trauma,neoplasia,pregnancy,lupus flares. ICU SLE-higher mortality.
![Page 52: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/52.jpg)
![Page 53: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/53.jpg)
![Page 54: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/54.jpg)
PPts of CAPS
![Page 55: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/55.jpg)
Catastrophic antiphospholipid syndrome
![Page 56: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/56.jpg)
A note on other syndromes Asymptomatic---??? Apl---risk factor,requires other trigger for APLS—double hit
theory. h/o thrombosis,LA,acl IgG---FIVE FOLD Probable– Lack the clinical criteria of vascular thrombosis or pregnancy
loss. Livedo,chorea,thrombocytopenia. Livedo reticularis the first manifestation—41% Seronegative Clinical manifestations but no identifiable ab Repeat testing---positive. Microangiopathic Microvascular---TTP,HELLP,CAPS Drug induced Infection assosciated malignancy
![Page 57: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/57.jpg)
DRUG induced Cardiac---procainamide,quinidine,propanolol,hydralazine. Neuroleptic or psychiatric—phenytoin,chlorpromazine. Other-interferon alpha,quinine,amoxicillin
Infection— Syphilis HCV HIV HTLV type 1 Malaria Septicemia.
![Page 58: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/58.jpg)
LAB DIAGNOSIS
APA---IgG,IgA,IgM SEVERAL antibodies are recognised Recently—antibodies against annexin V,protein C
IgM acl---HEMOLYTIC ANEMIA. IgG ACL –thrombosis False positive test result for syphilis ACL—membrane phospholipids LA-plasma coagulation molecules Elongates APTT,Kaolin clotting time,dilute russells viper
venom time.
![Page 59: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/59.jpg)
Kaolin clotting test
![Page 60: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/60.jpg)
Lab assessment
![Page 61: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/61.jpg)
INR
The ISI—1.0-2.0 INR—5 high chance of bleeding 0.5--- clot formation Normal range is 0.9-1.3 Warfarin ---2.0-3.0 Prosthetic valves—3.0-4.0
![Page 62: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/62.jpg)
LUPUS ANTICOAGULANT
LABORATORY artifact. Interferes with the action of phospholipid cofactors in the
coagulation cascade in lab assays—prolongation of time to clot—mimics anticoagulant response.
Misnomer—ass with thrombosis. Inhibits the formation of prothrombinase complex within
the coagulation cascade. It blocks the binding of prothrombin and factor Xa to
phospholipids---thrombin formation inhibited. It can be Ig G,A,M 10%of SLE Venous thrombosis
![Page 63: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/63.jpg)
How you diagnose LA
Normal Platelets-- poor plasma is mixed with patient’s plasma
If a clotting factor is deficient,the addition of normal plasma corrects the prolonged clotting time.
If the clotting time does not normalize ,an inhibitor is present.
The absence of a specific clotting factor inhibitor confirms that LA is present.
![Page 64: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/64.jpg)
What if LA,ACL are negative
If patient experiencing thrombosis or recurrent miscarriages
Order Antibodies to b2 gp1 Ab to phosphatidyl serine,ethonalamine,glycerol,inositol Annexin V Phosphatidyl choline.
![Page 65: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/65.jpg)
DRVVT
Detection of LA In vitro test ---ability of venom of russells viper to induce
thrombosis. Coagulant in venom directly activates factor X—turns
prothrombin to thrombin in presence of factor V and phospholipid.
In drvvt assay time is set to 23-27 sec A prolonged clotting time of 30 sec or greater that does not
correct with addition of an equal volume of normal plasma suggests the presence of LA.
Excess phospholipid is added. Normalised Both the tests are determined to a ratio. >1.2---may have.1.6 ---confirm. More sensitive than APTT for LA
![Page 66: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/66.jpg)
Diluted Russells viper venom test
![Page 67: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/67.jpg)
Imaging studies
For confirmation USG COLOR DOPPLER CT SCAN MRI 2D ECHO
Histology----non inflammatory bland thrombosis with no signs of perivascular inflammation or leukocytoclastic vasculitis.
![Page 68: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/68.jpg)
DVT
![Page 69: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/69.jpg)
DIFFERENTIAL DIAGNOSIS
Think of any other thrombophilic states before making a diagnosis of APLS.
Malignancy OCP Homocysteinemia Antithrombin 111 def Protein C,S def Factor V leiden mutation
![Page 70: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/70.jpg)
TREATMENT
Asymptomatic individuals in whom blood test findings are positive do not requires specific treatment.
In pregnancy---use heparin and aspirin Previously prednisolone was used—no benefit as per trials Increases premnaturity,hypertension. No beneficial role of immunoglobulins in pregnancy. 1.with one fetal loss or mulitple abortions---aspirin plus
heparin. Warfarin only after organogenesis is complete Nursing is safe
![Page 71: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/71.jpg)
Prophylactic therapy— Eliminate other risk factors Low dose aspirin,clopidogrel SLE—hydroxychloroquine—intrinsic antithrombotic
properties. Statins may be used—fluvastatin.
Thrombosis--- IV /sc heparin---warfarin Reasonable INR is 2.0-3.0 for venous,3.0 for
arterial,recurrent—3.0-4.0---think of bleeding if >5.0 Life long anticoagulation
![Page 72: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/72.jpg)
Obstetric--- Prophylaxis for with no h/o thrombosis Full anticoagulation with h/o thrombosis. Sc heparin,low dose aspirin With held at the time of delivery.
CAPS—steroids
Recurrent DVT ---ivc filter.
Patient education Avoid prolonged immobilization.
![Page 73: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/73.jpg)
Current recommendations
Primary thrombosis prevention---lack of evidence based approach. Arthritis Rheum 2004;50;s640-1
for sec prevention—life long warfarin. Duration,intensity ---still debate.
In case of fetal loss h/o-low dose aspirin+LMWH-----fail-----Ivig effective only in reports. Curr Rheumatol Report2002(4);379-86
CAPS—anticoagulation,steroids,IVIG,plasma exchange. Arthritis Rheumat 2003;48(12);3320-7
Elimination of reversible risk factorsProphylaxis during high risk periods are crucial
![Page 74: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/74.jpg)
![Page 75: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/75.jpg)
![Page 76: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/76.jpg)
![Page 77: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/77.jpg)
How much warfarin should be used?
Both moderate INR 2-3 and high intensity anticoagulation (INR 3-4) are similar protective in APS patients after the first thrombosis---NEJM 2003;349;1133-8,J Thromb Haemost 2005;3:848-53
Excess of minor bleeding in high intensity group. target of INR 2.5 High target in case of recurrence.
Intensity in case of arterial events is still deabte?????///
![Page 78: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/78.jpg)
No data to support primary prevention of stroke in asymptomatic carriers of APL.
Risk factors—use low dose aspirin. Anticoagulate patients with INR 3.0 Long term warfarin therapy.
How long should we use warfarin???/ Lifelong Recurrence may not be higher in APL patients on
discontinuation of warfarin—10% What is the effect of discontinuation—trials are going on..
![Page 79: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/79.jpg)
Is warfarin complete treatment?
Efficacy in microangiopathic nephropathy,valvular heart disease ,livedo reticularis, leg ulcers is not supported by data.
In asymptomatic patients???????///
178 persistently positive patients---thrombosis free were followed for three years witrhout anticoagulation---no patient developed thrombosis.
J Rheuma 2004,31;1560-7
![Page 80: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/80.jpg)
Alternatives to warfarin
Dipyridamole,ticlopidine,clopidogrel---sec prevention of non cardio embolic strokes---only clopidogrel effective.
Recurrence rate is 5-10% with these agents.
Direct thrombin inhibitors role ??? But can be used in HIT
CAPS---rituximab,an anti CD20 MONOCLONAL AB HYDROXYXHLOROQUINE Statins—fluvastatin decreases thrombus size.
![Page 81: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/81.jpg)
![Page 82: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/82.jpg)
Ximelagatran—first oral thrombin inhibitor. Neutralises clot bound thrombin. Melgatran—rapid onset of action,shorter half life. No interaction Superior to warfarin after TKRS. Cause LFT changes Not approved by FDA in 2004-----www.astrazeneca.com
![Page 83: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/83.jpg)
doses
Warfarin---5-15mg/day qd for 2-5 days INR 2.5-3.5 LMWH—low dose 20-40mg/day SC,1 mg/kg SC bid –high
dose. Unfractionated—SC 5000-10,000u q12h IV—5,000 U ---1000-2000U/Hr Weight based 80U/Kg ---18U/Kg/h iv APTT 2 times baseline----factor Xa assays in case of LA. aspirin 81mg/day Hydroxychloroquine—6-7mg/kg/d---200-400mg/d Cyclophosphamide 2-3 mg/kg/d PO OD, Steroids—prednisolone 1 mg/kg bw IV ig---400mg/kg/d iv for 5 days Statins ---atorva 10mg,pravastatin 40m g,fluvastatin 5 mg
![Page 84: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/84.jpg)
New drugs
Rituximab 1000mg iv for 2 doses.seperated by 2 weeks. Rate at 50mg/h
eculizumab
![Page 85: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/85.jpg)
FOLLOW UP
Frequent check ups Adequate patient education Avoidance of smoking Strict control with anticoagulants. In case of bleeding –hospital.
Normal healthy life
![Page 86: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/86.jpg)
TRIALS
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
by john hopkins university,nov 2009.
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome---JUNE 2006---JULY 2009---Individuals with APL and family h/o APL compared with APL patients with h/o of only othr rheumatic disorders.—observational
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus orAntiphospholipid Antibody Syndrome----
![Page 87: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/87.jpg)
Reliability of Point-of-Care INR Measurements in Patients With Antiphospholipid-Antibody SyndromeTreated With Warfarin----comparing with venupuncture
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE)
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid SyndromePatients
Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome(RITAPS)
![Page 88: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/88.jpg)
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome.
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT (HepASA)
Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
LOG on to clinicaltrials.gov
![Page 89: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/89.jpg)
future
Target based treatment
Specific complement inhibitors
Using anticoagulation in times of need.
Primary prevention drug
Alternative effective drug to warfarin.
![Page 90: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/90.jpg)
TAKE HOME MESSAGE
Think of APLS in a young female with thrombosis,fetal wastage.
Recurrent migraine headaches in a young female –do APL
INR to be individualized and mainatined at 2.0-3.0 Recurrent –3.0-4.0 LA—DRVVT HEPARIN –FACTOR XA IgG ACL –THROMBOSIS Ig M ACL—HEMOLYTIC ANEMIA LIVEDO RETICULARIS –THINK OF APLS CHOREA IN YOUNG –THINK OF APLS ACL –INCREASES WITH AGE ACL—ARTERIAL,LA—VENOUS LIFE LONG ANTICOAGULATION CAPS—ICU CARE
![Page 91: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/91.jpg)
SUMMARY
An autoimmune disease ,acquired, assosciated with heterogenous antibodies which act through various mechanisms—leading to thrombosis---diagnosis by sapporo criteria—confirmation on thrombosis for diagnosis---seperation of lab tests by 12 weeks---warfarin life long therapy—heparin in pregnancy----CAPS– acute emergency---INR to be monitored----risk to be explained.---future trends of target therapy awaited.
![Page 92: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/92.jpg)
![Page 93: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/93.jpg)
References,sites www.emedicine.com
www.lupus.org
www.wikipedia.com
www.lupusawarenessandresearch.com
www.japi.org
www.clinicaltrials.gov
HARRISON’S PRINCIPLES OF INTERNAL MEDICINE,17 ED.
![Page 94: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/94.jpg)
![Page 95: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/95.jpg)
Thank you SAGITTARI
AN
![Page 96: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/96.jpg)
discussion
1.what you do in a case of a female who is diagnosed as having APLS,was kept on warfarin –had previous miscarriage—now wants to conceive----?
Ans—stop warfarin if the patient wants to conceive.and put her on heparin.again shift her to warfarin postpartum.
You said after she diagnosed as pregnant
![Page 97: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/97.jpg)
2.what you will do in 2 cases with status epilepticus---patient treated,both being young was advised—CT scan brain—one had infarct,other normal,both APL being positive .with no h/o of previous thrombosis or APL postivity
Ans—the APL positivity to be confirmed again after 12 weeks.if they are positive then attribute it to APLS.the false positivty of APL ab are high---the drugs used for the treatment of status epilepticus—phenytoin –may also cause an increase in APL ab.in both the test to be confirmed after 12 weeks.and treatment of thrombosis to be started at that time
You said treatment for the one having thrombosis to be taken.
![Page 98: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/98.jpg)
queries
Your vocabulary is not appropriate,adequate. You were stopping in the middle. You could not explain the drvvt. You could not explain CAPS adequately.
![Page 99: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/99.jpg)
Read about
What is the one causing LA to lead to thrombosis or per se it causes thrombosis?
Normally coagulation takes place on exposure of the endothelium—how is the endothelium exposed in case of APLS?
What were the patients with pregnancy using in case of PROMISSE trial?
Normally complement activation leads to hemolysis—how is it causing thrombosi?
Annexin v ab to be explained? Pathogenesis to be explained? LA is a coagulant not an anticoagulant.
![Page 100: Antiphospholipid antibody syndrome](https://reader031.vdocuments.site/reader031/viewer/2022012318/55505e87b4c905ae3f8b5245/html5/thumbnails/100.jpg)
All were present during my presentation. Juniors were present
Total duration was 42 min.—exhaustive. I lost the tempo. Date of presentation—23-06-2010.